This HTML5 document contains 97 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n26http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00818/identifier/chemspider/
n21http://linked.opendata.cz/resource/drugbank/dosage/
n20http://www.drugs.com/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00818/identifier/chebi/
n27http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB00818/identifier/wikipedia/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00818/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00818/identifier/kegg-compound/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00818/identifier/pdb/
n19http://linked.opendata.cz/resource/drugbank/patent/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n31http://linked.opendata.cz/resource/drugbank/drug/DB00818/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n25http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00818/identifier/pubchem-substance/
n10http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00818/identifier/kegg-drug/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00818/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/ontology/sukl/drug/
n30http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00818/identifier/national-drug-code-directory/

Statements

Subject Item
n2:DB00818
rdf:type
n3:Drug
n3:description
Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries.
n3:dosage
n21:271B4368-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Vasile B, Rasulo F, Candiani A, Latronico N: The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003 Sep;29(9):1417-25. Epub 2003 Aug 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12904852 # Ke JJ, Zhan J, Feng XB, Wu Y, Rao Y, Wang YL: A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro- and anti-inflammatory cytokines in patients undergoing open cholecystectomy. Anaesth Intensive Care. 2008 Jan;36(1):74-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18326136 # Hong JY, Kang YS, Kil HK: Anaesthesia for day case excisional breast biopsy: propofol-remifentanil compared with sevoflurane-nitrous oxide. Eur J Anaesthesiol. 2008 Feb 26;:1-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18298873
n3:group
approved investigational
n3:halfLife
Initial distribution phase t<sub>1/2&alpha;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&beta;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&gamma;</sub>=1.5-31 hours.
n3:indication
Used for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus.
n3:manufacturer
n5:271B4361-363D-11E5-9242-09173F13E4C5 n5:271B435F-363D-11E5-9242-09173F13E4C5 n5:271B4360-363D-11E5-9242-09173F13E4C5 n5:271B435E-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00818 n27:DB00818
dcterms:title
Propofol
adms:identifier
n12:0409-4699-30 n13:PFL n14:C07523 n15:D00549 n16:DB00818 n17:8495 n18:4774 n22:Propofol n28:46504991 n29:PA451141 n31:4943
n3:mechanismOfAction
The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid (GABA) through GABA-A receptors.
n3:packager
n5:271B435D-363D-11E5-9242-09173F13E4C5 n5:271B4359-363D-11E5-9242-09173F13E4C5 n5:271B435A-363D-11E5-9242-09173F13E4C5 n5:271B4357-363D-11E5-9242-09173F13E4C5 n5:271B4356-363D-11E5-9242-09173F13E4C5 n5:271B435B-363D-11E5-9242-09173F13E4C5 n5:271B435C-363D-11E5-9242-09173F13E4C5 n5:271B4358-363D-11E5-9242-09173F13E4C5
n3:patent
n19:2212794 n19:5714520
n3:routeOfElimination
It is chiefly eliminated by hepatic conjugation to inactive metabolites which are excreted by the kidney.
n3:synonym
2,6-Bis(1-methylethyl)phenol Propofol Propofolum Rapinovet Disoprofol Disoprivan Diprivan 2,6-Diisopropylphenol
n3:toxicity
Overdosage may increase pharmacologic and adverse effects or cause death. <p>IV LD<sub>50</sub>=53 mg/kg (mice), 42 mg/kg (rats). Oral LD<sub>50</sub> (as a solution in soybean oil)=1230 mg/kg (mice), 600 mg/kg (rats)</p>
n3:volumeOfDistribution
* 60 L/kg [healthy adults]
n23:hasAHFSCode
n24:28-04-92
n3:proteinBinding
95 to 99%, primarily to serum albumin and hemoglobin
n3:synthesisReference
John R. Carpenter, "Propofol-based anesthetic and method of making same." U.S. Patent US6150423, issued May, 1977.
n25:hasConcept
n26:M0024130
foaf:page
n10:propof.htm n20:propofol.html
n3:IUPAC-Name
n4:271B436D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4373-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4372-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B436F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4370-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4371-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4383-363D-11E5-9242-09173F13E4C5 n4:271B436B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4386-363D-11E5-9242-09173F13E4C5 n4:271B4369-363D-11E5-9242-09173F13E4C5 n4:271B436C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B436A-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4387-363D-11E5-9242-09173F13E4C5
n23:hasATCCode
n30:N01AX10
n3:H-Bond-Acceptor-Count
n4:271B4379-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B437A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4374-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4375-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4377-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4376-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4378-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapid - time to onset of unconsciousness is 15-30 seconds, due to rapid distribution from plasma to the CNS. Distribution is so rapid that peak plasma concentrations cannot be readily measured. Duration of action is 5-10 minutes.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
2078-54-8
n3:category
n3:clearance
* 23 - 50 mL/kg/min * 1.6 - 3.4 L/min [70 Kg adults]
n3:containedIn
n8:271B4367-363D-11E5-9242-09173F13E4C5 n8:271B4362-363D-11E5-9242-09173F13E4C5 n8:271B4363-363D-11E5-9242-09173F13E4C5 n8:271B4364-363D-11E5-9242-09173F13E4C5 n8:271B4365-363D-11E5-9242-09173F13E4C5 n8:271B4366-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B437F-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B4385-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4381-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4382-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4384-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B437E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B437D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4380-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B436E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B437B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B437C-363D-11E5-9242-09173F13E4C5